Amgen Inc. (VIE:AMGN)

Austria flag Austria · Delayed Price · Currency is EUR
284.90
-9.70 (-3.29%)
At close: Dec 5, 2025
8.04%
Market Cap 157.07B
Revenue (ttm) 30.66B
Net Income (ttm) 5.97B
Shares Out n/a
EPS (ttm) 11.02
PE Ratio 26.31
Forward PE 16.37
Dividend 8.52 (2.92%)
Ex-Dividend Date Nov 21, 2025
Volume 129
Average Volume 127
Open 291.80
Previous Close 294.60
Day's Range 284.90 - 292.45
52-Week Range 230.50 - 307.30
Beta n/a
RSI 51.34
Earnings Date Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1980
Employees 28,000
Stock Exchange Vienna Stock Exchange
Ticker Symbol AMGN
Full Company Profile

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD Financial Statements

News

There is no news available yet.